Global Colorectal Cancer Drugs Market 2015-2019 is a new market research publication announced by Reportstack. Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Colorectal cancer is the third most common cancer in the US. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.The analysts forecast that the global colorectal cancer drugs market to grow at a CAGR of 3.62% over the period 2014-2019.

To access full report with TOC, please visit Global Colorectal Cancer Drugs Market 2015-2019.

Covered in this ReportThis report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from sales of various drugs used in the treatment of colorectal cancer. Based on the type of molecule, the market is grouped into two categories:• Biologics• Small moleculesBased on the route of administration, the market is grouped into two categories:• Oral• ParenteralThis report covers the present scenario and the growth prospects of the global colorectal cancer drugs market for the period 2015-2019 in the following regions: • Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil• EMEA: The principal countries focused upon in this region are the UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE. Germany, Italy, and the UK are the leading European countries in terms of elderly population• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors as well as the competitive performances of their product portfolios in the market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.The report, Global Colorectal Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, EMEA, and APAC; it also covers the global colorectal cancer drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions• Americas • APAC• EMEA Key Vendors• Amgen• Bayer• Bristol-Myers Squibb• F. Hoffmann-La Roche• Merck SeronoOther Prominent Vendors• Accord Healthcare• Advenchen Laboratories• Aeterna Zentaris• AstraZeneca• Bavarian Nordic• Biothera• Boehringer Ingelheim• Daiichi Sankyo• Debiopharm• Eisai• Eli Lilly• Immodulon Therapeutics• Mologen• Mylan• Nektar Therapeutics• Oncothyreon• Otsuka Pharmaceutical• Precision Biologics• Sun Pharmaceutical• Symphogen• Taiho• Takeda• Teva• ThromboGenics• Xbiotech• Yakult Honsha Market Driver• Increase in population of patients• For a full, detailed list, view our reportMarket Challenge• Loss of patent exclusivity• For a full, detailed list, view our reportMarket Trend• Dominance of biologics• For a full, detailed list, view our reportKey Questions Answered in this Report• What will the market size be in 2019 and what will the growth rate be?• What are the key market trends?• What is driving this market?• What are the challenges to market growth?• Who are the key vendors in this market space?• What are the market opportunities and threats faced by the key vendors?• What are the strengths and weaknesses of the key vendors?

Companies Mentioned

Amgen, Bayer, Bristol-Myers Squibb, F. Hoffmann-La Roche, Merck Serono, Accord Healthcare, Advenchen Laboratories, Aeterna Zentaris, AstraZeneca, Bavarian Nordic, Biothera, Boehringer Ingelheim, Daiichi Sankyo, Debiopharm, Eisai, Eli Lilly, Immodulon Therapeutics, Mologen, Mylan, Nektar Therapeutics, Oncothyreon, Otsuka Pharmaceutical, Precision Biologics, Sun Pharmaceutical, Symphogen, Taiho, Takeda, Teva, ThromboGenics, Xbiotech, Yakult Honsha

Contact:

Debora WhiteManager - Marketing debora@reportstack.comPh: +1-888-789-6604Reportstack Market Research###